Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome

Ludwine Messiaen, Suxia Yao, Hilde Brems, Tom Callens, Achara Sathienkijkanchai, Ellen Denayer, Emily Spencer, Pamela Arn, Dusica Babovic-Vuksanovic, Carolyn Bay, Gary Bobele, Bruce H. Cohen, Luis Escobar, Deborah Eunpu, Theresa Grebe, Robert Greenstein, Rachel Hachen, Mira Irons, David Kronn, Edmond LemireKathleen Leppig, Cynthia Lim, Marie McDonald, Vinodh Narayanan, Amy Pearn, Robert Pedersen, Berkley Powell, Lawrence R. Shapiro, David Skidmore, David Tegay, Heidi Thiese, Elaine H. Zackai, Raymon Vijzelaar, Koji Taniguchi, Toranoshin Ayada, Fuyuki Okamoto, Akihiko Yoshimura, Annabel Parret, Bruce Korf, Eric Legius

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Context: Autosomal dominant inactivating sprouty-related EVH1 domain-containing protein 1 (SPRED1) mutations have recently been described in individuals presenting mainly with café au lait macules (CALMs), axillary freckling, and macrocephaly. The extent of the clinical spectrum of this new disorder needs further delineation. Objective: To determine the frequency, mutational spectrum, and phenotype of neurofibromatosis type 1-like syndrome (NFLS) in a large cohort of patients. Design, Setting, and Participants: In a cross-sectional study, 23 unrelated probands carrying a SPRED1 mutation identified through clinical testing participated with their families in a genotype-phenotype study (2007-2008). In a second cross-sectional study, 1318 unrelated anonymous samples collected in 2003-2007 from patients with a broad range of signs typically found in neurofibromatosis type 1 (NF1) but no detectable NF1 germline mutation underwent SPRED1 mutation analysis. Main Outcome Measures: Comparison of aggregated clinical features in patients with or without a SPRED1 or NF1 mutation. Functional assays were used to evaluate the pathogenicity of missense mutations. Results: Among 42 SPRED1-positive individuals from the clinical cohort, 20 (48%; 95% confidence interval [CI], 32%-64%) fulfilled National Institutes of Health (NIH) NF1 diagnostic criteria based on the presence of more than 5 CALMs with or without freckling or an NF1-compatible family history. None of the 42 SPRED1-positive individuals (0%; 95% CI, 0%-7%) had discrete cutaneous or plexiform neurofibromas, typical NF1 osseous lesions, or symptomatic optic pathway gliomas. In the anonymous cohort of 1318 individuals, 34 different SPRED1 mutations in 43 probands were identified: 27 pathogenic mutations in 34 probands and 7 probable nonpathogenic missense mutations in 9 probands. Of 94 probands with familial CALMs with or without freckling and no other NF1 features, 69 (73%; 95% CI, 63%-80%) had an NF1 mutation and 18 (19%; 95% CI, 12%-29%) had a pathogenic SPRED1 mutation. In the anonymous cohort, 1.9% (95% CI, 1.2%-2.9%) of individuals with the clinical diagnosis of NF1 according to the NIH criteria had NFLS. Conclusions: A high SPRED1 mutation detection rate was found in NF1 mutation-negative families with an autosomal dominant phenotype of CALMs with or without freckling and no other NF1 features. Among individuals in this study, NFLS was not associated with the peripheral and central nervous system tumors seen in NF1.

Original languageEnglish
Pages (from-to)2111-2118
Number of pages8
JournalJAMA - Journal of the American Medical Association
Volume302
Issue number19
DOIs
Publication statusPublished - 2009

Fingerprint

Neurofibromatosis 1
Mutation
Confidence Intervals
National Institutes of Health (U.S.)
Missense Mutation
Phenotype
Legius syndrome
Cross-Sectional Studies
Plexiform Neurofibroma
Optic Nerve Glioma
Megalencephaly
Protein Domains
Central Nervous System Neoplasms
Germ-Line Mutation
Peripheral Nervous System
Mutation Rate
Virulence
Genotype
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Messiaen, L., Yao, S., Brems, H., Callens, T., Sathienkijkanchai, A., Denayer, E., ... Legius, E. (2009). Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA - Journal of the American Medical Association, 302(19), 2111-2118. https://doi.org/10.1001/jama.2009.1663

Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. / Messiaen, Ludwine; Yao, Suxia; Brems, Hilde; Callens, Tom; Sathienkijkanchai, Achara; Denayer, Ellen; Spencer, Emily; Arn, Pamela; Babovic-Vuksanovic, Dusica; Bay, Carolyn; Bobele, Gary; Cohen, Bruce H.; Escobar, Luis; Eunpu, Deborah; Grebe, Theresa; Greenstein, Robert; Hachen, Rachel; Irons, Mira; Kronn, David; Lemire, Edmond; Leppig, Kathleen; Lim, Cynthia; McDonald, Marie; Narayanan, Vinodh; Pearn, Amy; Pedersen, Robert; Powell, Berkley; Shapiro, Lawrence R.; Skidmore, David; Tegay, David; Thiese, Heidi; Zackai, Elaine H.; Vijzelaar, Raymon; Taniguchi, Koji; Ayada, Toranoshin; Okamoto, Fuyuki; Yoshimura, Akihiko; Parret, Annabel; Korf, Bruce; Legius, Eric.

In: JAMA - Journal of the American Medical Association, Vol. 302, No. 19, 2009, p. 2111-2118.

Research output: Contribution to journalArticle

Messiaen, L, Yao, S, Brems, H, Callens, T, Sathienkijkanchai, A, Denayer, E, Spencer, E, Arn, P, Babovic-Vuksanovic, D, Bay, C, Bobele, G, Cohen, BH, Escobar, L, Eunpu, D, Grebe, T, Greenstein, R, Hachen, R, Irons, M, Kronn, D, Lemire, E, Leppig, K, Lim, C, McDonald, M, Narayanan, V, Pearn, A, Pedersen, R, Powell, B, Shapiro, LR, Skidmore, D, Tegay, D, Thiese, H, Zackai, EH, Vijzelaar, R, Taniguchi, K, Ayada, T, Okamoto, F, Yoshimura, A, Parret, A, Korf, B & Legius, E 2009, 'Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome', JAMA - Journal of the American Medical Association, vol. 302, no. 19, pp. 2111-2118. https://doi.org/10.1001/jama.2009.1663
Messiaen, Ludwine ; Yao, Suxia ; Brems, Hilde ; Callens, Tom ; Sathienkijkanchai, Achara ; Denayer, Ellen ; Spencer, Emily ; Arn, Pamela ; Babovic-Vuksanovic, Dusica ; Bay, Carolyn ; Bobele, Gary ; Cohen, Bruce H. ; Escobar, Luis ; Eunpu, Deborah ; Grebe, Theresa ; Greenstein, Robert ; Hachen, Rachel ; Irons, Mira ; Kronn, David ; Lemire, Edmond ; Leppig, Kathleen ; Lim, Cynthia ; McDonald, Marie ; Narayanan, Vinodh ; Pearn, Amy ; Pedersen, Robert ; Powell, Berkley ; Shapiro, Lawrence R. ; Skidmore, David ; Tegay, David ; Thiese, Heidi ; Zackai, Elaine H. ; Vijzelaar, Raymon ; Taniguchi, Koji ; Ayada, Toranoshin ; Okamoto, Fuyuki ; Yoshimura, Akihiko ; Parret, Annabel ; Korf, Bruce ; Legius, Eric. / Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. In: JAMA - Journal of the American Medical Association. 2009 ; Vol. 302, No. 19. pp. 2111-2118.
@article{85b3aff648904b1cbde8624e99b3a500,
title = "Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome",
abstract = "Context: Autosomal dominant inactivating sprouty-related EVH1 domain-containing protein 1 (SPRED1) mutations have recently been described in individuals presenting mainly with caf{\'e} au lait macules (CALMs), axillary freckling, and macrocephaly. The extent of the clinical spectrum of this new disorder needs further delineation. Objective: To determine the frequency, mutational spectrum, and phenotype of neurofibromatosis type 1-like syndrome (NFLS) in a large cohort of patients. Design, Setting, and Participants: In a cross-sectional study, 23 unrelated probands carrying a SPRED1 mutation identified through clinical testing participated with their families in a genotype-phenotype study (2007-2008). In a second cross-sectional study, 1318 unrelated anonymous samples collected in 2003-2007 from patients with a broad range of signs typically found in neurofibromatosis type 1 (NF1) but no detectable NF1 germline mutation underwent SPRED1 mutation analysis. Main Outcome Measures: Comparison of aggregated clinical features in patients with or without a SPRED1 or NF1 mutation. Functional assays were used to evaluate the pathogenicity of missense mutations. Results: Among 42 SPRED1-positive individuals from the clinical cohort, 20 (48{\%}; 95{\%} confidence interval [CI], 32{\%}-64{\%}) fulfilled National Institutes of Health (NIH) NF1 diagnostic criteria based on the presence of more than 5 CALMs with or without freckling or an NF1-compatible family history. None of the 42 SPRED1-positive individuals (0{\%}; 95{\%} CI, 0{\%}-7{\%}) had discrete cutaneous or plexiform neurofibromas, typical NF1 osseous lesions, or symptomatic optic pathway gliomas. In the anonymous cohort of 1318 individuals, 34 different SPRED1 mutations in 43 probands were identified: 27 pathogenic mutations in 34 probands and 7 probable nonpathogenic missense mutations in 9 probands. Of 94 probands with familial CALMs with or without freckling and no other NF1 features, 69 (73{\%}; 95{\%} CI, 63{\%}-80{\%}) had an NF1 mutation and 18 (19{\%}; 95{\%} CI, 12{\%}-29{\%}) had a pathogenic SPRED1 mutation. In the anonymous cohort, 1.9{\%} (95{\%} CI, 1.2{\%}-2.9{\%}) of individuals with the clinical diagnosis of NF1 according to the NIH criteria had NFLS. Conclusions: A high SPRED1 mutation detection rate was found in NF1 mutation-negative families with an autosomal dominant phenotype of CALMs with or without freckling and no other NF1 features. Among individuals in this study, NFLS was not associated with the peripheral and central nervous system tumors seen in NF1.",
author = "Ludwine Messiaen and Suxia Yao and Hilde Brems and Tom Callens and Achara Sathienkijkanchai and Ellen Denayer and Emily Spencer and Pamela Arn and Dusica Babovic-Vuksanovic and Carolyn Bay and Gary Bobele and Cohen, {Bruce H.} and Luis Escobar and Deborah Eunpu and Theresa Grebe and Robert Greenstein and Rachel Hachen and Mira Irons and David Kronn and Edmond Lemire and Kathleen Leppig and Cynthia Lim and Marie McDonald and Vinodh Narayanan and Amy Pearn and Robert Pedersen and Berkley Powell and Shapiro, {Lawrence R.} and David Skidmore and David Tegay and Heidi Thiese and Zackai, {Elaine H.} and Raymon Vijzelaar and Koji Taniguchi and Toranoshin Ayada and Fuyuki Okamoto and Akihiko Yoshimura and Annabel Parret and Bruce Korf and Eric Legius",
year = "2009",
doi = "10.1001/jama.2009.1663",
language = "English",
volume = "302",
pages = "2111--2118",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "19",

}

TY - JOUR

T1 - Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome

AU - Messiaen, Ludwine

AU - Yao, Suxia

AU - Brems, Hilde

AU - Callens, Tom

AU - Sathienkijkanchai, Achara

AU - Denayer, Ellen

AU - Spencer, Emily

AU - Arn, Pamela

AU - Babovic-Vuksanovic, Dusica

AU - Bay, Carolyn

AU - Bobele, Gary

AU - Cohen, Bruce H.

AU - Escobar, Luis

AU - Eunpu, Deborah

AU - Grebe, Theresa

AU - Greenstein, Robert

AU - Hachen, Rachel

AU - Irons, Mira

AU - Kronn, David

AU - Lemire, Edmond

AU - Leppig, Kathleen

AU - Lim, Cynthia

AU - McDonald, Marie

AU - Narayanan, Vinodh

AU - Pearn, Amy

AU - Pedersen, Robert

AU - Powell, Berkley

AU - Shapiro, Lawrence R.

AU - Skidmore, David

AU - Tegay, David

AU - Thiese, Heidi

AU - Zackai, Elaine H.

AU - Vijzelaar, Raymon

AU - Taniguchi, Koji

AU - Ayada, Toranoshin

AU - Okamoto, Fuyuki

AU - Yoshimura, Akihiko

AU - Parret, Annabel

AU - Korf, Bruce

AU - Legius, Eric

PY - 2009

Y1 - 2009

N2 - Context: Autosomal dominant inactivating sprouty-related EVH1 domain-containing protein 1 (SPRED1) mutations have recently been described in individuals presenting mainly with café au lait macules (CALMs), axillary freckling, and macrocephaly. The extent of the clinical spectrum of this new disorder needs further delineation. Objective: To determine the frequency, mutational spectrum, and phenotype of neurofibromatosis type 1-like syndrome (NFLS) in a large cohort of patients. Design, Setting, and Participants: In a cross-sectional study, 23 unrelated probands carrying a SPRED1 mutation identified through clinical testing participated with their families in a genotype-phenotype study (2007-2008). In a second cross-sectional study, 1318 unrelated anonymous samples collected in 2003-2007 from patients with a broad range of signs typically found in neurofibromatosis type 1 (NF1) but no detectable NF1 germline mutation underwent SPRED1 mutation analysis. Main Outcome Measures: Comparison of aggregated clinical features in patients with or without a SPRED1 or NF1 mutation. Functional assays were used to evaluate the pathogenicity of missense mutations. Results: Among 42 SPRED1-positive individuals from the clinical cohort, 20 (48%; 95% confidence interval [CI], 32%-64%) fulfilled National Institutes of Health (NIH) NF1 diagnostic criteria based on the presence of more than 5 CALMs with or without freckling or an NF1-compatible family history. None of the 42 SPRED1-positive individuals (0%; 95% CI, 0%-7%) had discrete cutaneous or plexiform neurofibromas, typical NF1 osseous lesions, or symptomatic optic pathway gliomas. In the anonymous cohort of 1318 individuals, 34 different SPRED1 mutations in 43 probands were identified: 27 pathogenic mutations in 34 probands and 7 probable nonpathogenic missense mutations in 9 probands. Of 94 probands with familial CALMs with or without freckling and no other NF1 features, 69 (73%; 95% CI, 63%-80%) had an NF1 mutation and 18 (19%; 95% CI, 12%-29%) had a pathogenic SPRED1 mutation. In the anonymous cohort, 1.9% (95% CI, 1.2%-2.9%) of individuals with the clinical diagnosis of NF1 according to the NIH criteria had NFLS. Conclusions: A high SPRED1 mutation detection rate was found in NF1 mutation-negative families with an autosomal dominant phenotype of CALMs with or without freckling and no other NF1 features. Among individuals in this study, NFLS was not associated with the peripheral and central nervous system tumors seen in NF1.

AB - Context: Autosomal dominant inactivating sprouty-related EVH1 domain-containing protein 1 (SPRED1) mutations have recently been described in individuals presenting mainly with café au lait macules (CALMs), axillary freckling, and macrocephaly. The extent of the clinical spectrum of this new disorder needs further delineation. Objective: To determine the frequency, mutational spectrum, and phenotype of neurofibromatosis type 1-like syndrome (NFLS) in a large cohort of patients. Design, Setting, and Participants: In a cross-sectional study, 23 unrelated probands carrying a SPRED1 mutation identified through clinical testing participated with their families in a genotype-phenotype study (2007-2008). In a second cross-sectional study, 1318 unrelated anonymous samples collected in 2003-2007 from patients with a broad range of signs typically found in neurofibromatosis type 1 (NF1) but no detectable NF1 germline mutation underwent SPRED1 mutation analysis. Main Outcome Measures: Comparison of aggregated clinical features in patients with or without a SPRED1 or NF1 mutation. Functional assays were used to evaluate the pathogenicity of missense mutations. Results: Among 42 SPRED1-positive individuals from the clinical cohort, 20 (48%; 95% confidence interval [CI], 32%-64%) fulfilled National Institutes of Health (NIH) NF1 diagnostic criteria based on the presence of more than 5 CALMs with or without freckling or an NF1-compatible family history. None of the 42 SPRED1-positive individuals (0%; 95% CI, 0%-7%) had discrete cutaneous or plexiform neurofibromas, typical NF1 osseous lesions, or symptomatic optic pathway gliomas. In the anonymous cohort of 1318 individuals, 34 different SPRED1 mutations in 43 probands were identified: 27 pathogenic mutations in 34 probands and 7 probable nonpathogenic missense mutations in 9 probands. Of 94 probands with familial CALMs with or without freckling and no other NF1 features, 69 (73%; 95% CI, 63%-80%) had an NF1 mutation and 18 (19%; 95% CI, 12%-29%) had a pathogenic SPRED1 mutation. In the anonymous cohort, 1.9% (95% CI, 1.2%-2.9%) of individuals with the clinical diagnosis of NF1 according to the NIH criteria had NFLS. Conclusions: A high SPRED1 mutation detection rate was found in NF1 mutation-negative families with an autosomal dominant phenotype of CALMs with or without freckling and no other NF1 features. Among individuals in this study, NFLS was not associated with the peripheral and central nervous system tumors seen in NF1.

UR - http://www.scopus.com/inward/record.url?scp=71749103918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71749103918&partnerID=8YFLogxK

U2 - 10.1001/jama.2009.1663

DO - 10.1001/jama.2009.1663

M3 - Article

C2 - 19920235

AN - SCOPUS:71749103918

VL - 302

SP - 2111

EP - 2118

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 19

ER -